Rapidly progressive fatal hemorrhagic pneumonia caused by stenotrophomonas maltophilia in hematologic malignancy

Transplant Infectious Disease

Volumn 14, Issue 4, 2012, Pages 355-363

  Araoka, H ^a   Fujii, T ^a   Izutsu, K ^a   Kimura, M ^a   Nishida, A ^a   Ishiwata, K ^a   Nakano, N ^a   Tsuji, M ^a   Yamamoto, H ^a   Asano Mori, Y ^a   Uchida, N ^a   Wake, A ^a   Taniguchi, S ^a   Yoneyama, A ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hematologic malignancy; Hematopoietic stem cell transplantation; Incidence; Neutropenia; Pneumonia; Stenotrophomonas maltophilia

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; HYDROCORTISONE; LEVOFLOXACIN; MEROPENEM; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TACROLIMUS; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SENSITIVITY; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HEMORRHAGIC PNEUMONIA; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; LEUKOCYTE COUNT; LYMPHOMA; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL TIME;

ADULT; ANTI-BACTERIAL AGENTS; BLOOD; CULTURE MEDIA; DISEASE PROGRESSION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; STENOTROPHOMONAS MALTOPHILIA; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84865185870     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00710.x     Document Type: Article

References (27)

1. Ortín X, Jaen-Martinez J, Rodríguez-Luaces M, Alvaro T, Font L. Fatal pulmonary hemorrhage in a patient with myelodysplastic syndrome and fulminant pneumonia caused by Stenotrophomonas maltophilia. Infection 2007; 35 (3): 201-202.
2. Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005; 25 (5): 911-914.
3. Fujita J, Yamadori I, Xu G, et al. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Resp Med 1996; 90 (1): 35-38.
4. Elsner HA, Dührsen U, Hollwitz B, Kaulfers PM, Hossfeld DK. Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia. Ann Hematol 1997; 74 (4): 155-161.
5. Takahashi N, Yoshioka T, Kameoka Y, et al. Fatal hemorrhagic pneumonia caused by Stenotrophomanas maltophilia in a patient with non-Hodgkin lymphoma. J Infect Chemother 2011; 17 (6): 858-862.
6. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45 (12): 1602-1609.
7. Meyer E, Schwab F, Gastmeier P, Ruden H, Daschner FD. Is the prevalence of Stenotrophomonas maltophilia isolation and nosocomial infection increasing in intensive care units? Eur J Clin Microbiol Infect Dis 2006; 25 (11): 711-714.
8. Fujitani S, Yu VL. Quantitative cultures for diagnosing ventilator-associated pneumonia: a critique. Clin Infect Dis 2006; 43 (Suppl 2): S106-S113.
9. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28 (7): 825-831.
10. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 (Suppl 1): S81-S87.
11. Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of Stenotrophomonas (Xanthomonas) maltophilia respiratory infection. Sem Resp Crit Care Med 2000; 21 (4): 349-355.
12. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9 (5): 312-323.
13. Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis 2010; 29 (5): 605-608.
14. Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45 (2): 413-419.
15. Walsh TR, MacGowan AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41 (7): 1460-1464.
16. Alonso A, Martínez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44 (11): 3079-3086.
17. Ba BB, Feghali H, Arpin C, Saux MC, Quentin C. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2004; 48 (3): 946-953.
18. Okazaki A, Avison MB. Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2007; 51 (1): 359-360.
19. Li XZ, Zhang L, McKay GA, Poole K. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 2003; 51 (4): 803-811.
20. Lambert T, Ploy MC, Denis F, Courvalin P. Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1999; 43 (10): 2366-2371.
21. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48 (1): 168-171.
22. Poulos CD, Matsumura SO, Willey BM, Low DE, McGreer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995; 39 (10): 2220-2223.
23. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative acitivity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45 (3): 363-365.
24. Valdezate S, Vindel A, Baquero F, Canton R. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 1999; 18 (12): 908-911.
25. Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005; 51 (1): 39-43.
26. Vartivarian SE, Anaissie EJ, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38 (3): 624-627.
27. Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT); American Society of Blood and Marrow Transplantation (ASBMT); Canadian Blood and Marrow Transplant Group (CBMTG); Infectious Disease Society of America (IDSA); Society for Healthcare Epidemiology of America (SHEA); Association of Medical Microbiology and Infectious Diseases Canada (AMMI); Centers for Disease Control and Prevention (CDC). Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009; 44 (8): 453-558.